The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice.
Epigallocatechin gallate (EGCG) is a constituent of green tea, and increasing evidence suggests that EGCG has neuroprotective effects on oxidative stress-injured neuronal cells, especially motoneurons. Although the neuroprotective effects of EGCG have been demonstrated in Parkinson's and Alzheimer's diseases and ischemic stroke models, there has been no report on the effect of EGCG on an in vivo model of amyotrophic lateral sclerosis (ALS). This study was undertaken to evaluate the effect of EGCG on ALS model mice with the human G93A mutated Cu/Zn-superoxide dismutase (SOD1) gene. We treated each group of 11 ALS model mice with EGCG (1.5, 2.9, and 5.8 microg/g body weight), dissolved in 0.5 ml of 0.9% sterile NaCl, and one group of 11 with 0.5 ml of 0.9% sterile NaCl (control group) intraorally every day after 60 days of age (presymptomatic treatment). The treatment of more than 2.9 microg EGCG/g body weight significantly prolonged the symptom onset and life span, preserved more survival signals, and attenuated death signals. These data suggest that EGCG could be a potential therapeutic candidate for ALS as a disease-modifying agent.
Koh
Seong-Ho
SH
Department of Neurology, Institute of Biomedical Science, College of Medicine, Hanyang University, #17 Haengdang-dong, Seongdong-gu, Seoul 133-791, Republic of Korea.
Lee
Sang Mok
SM
Kim
Hyun Young
HY
Lee
Kyu-Yong
KY
Lee
Young Joo
YJ
Kim
Hee-Tae
HT
Kim
Juhan
J
Kim
Myung-Ho
MH
Hwang
Myung Sil
MS
Song
Chiwon
C
Yang
Ki-Wha
KW
Lee
Kwang Woo
KW
Kim
Seung Hyun
SH
Kim
Ok-Hee
OH
D000690:Amyotrophic Lateral Sclerosis / Q000517:prevention & control*; D000818:Animals; D015153:Blotting, Western; D053148:Caspase 3; D020169:Caspases / Q000187:drug effects / Q000378:metabolism; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D018450:Disease Progression; D038362:Glycogen Synthase Kinase 3 / Q000187:drug effects / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects*; D009154:Mutation; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D019869:Phosphatidylinositol 3-Kinases / Q000187:drug effects / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects; D013482:Superoxide Dismutase / Q000235:genetics; D000072105:Superoxide Dismutase-1
D018696:Neuroprotective Agents; C000606290:SOD1 protein, human; D002392:Catechin; C045651:epigallocatechin gallate; C000606291:Sod1 protein, mouse; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D019869:Phosphatidylinositol 3-Kinases; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; C505407:CASP3 protein, human; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases